Pancreatic Cancer Research

ResearcherUniversity of PisaActive in the last 2 years

Frederike Dijk

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-3970-6601; OpenAlex author ID A5018956853. Sources: OpenAlex.

Their work

Papers
28 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
89
Papers, trials and grants by year

2012: 1 paper · 2013: none · 2014: none · 2015: none · 2016: 2 papers · 2017: none · 2018: 4 papers · 2019: none · 2020: 6 papers · 2021: 2 papers · 2022: 3 papers · 2023: 4 papers · 2024: 3 papers · 2025: 1 paper · 2026: 2 papers

Papers 28

  1. Transcriptome-Based Classification of Resected Pancreatic Ductal Adenocarcinoma Enhances Prognostic Modelling Accuracy of Overall Survival Following Adjuvant T… Co-author DOI 10.1002/ijc.70519↗
  2. WNT7B drives a program for pancreatic cancer subtype switching and progression. Co-author DOI 10.1016/j.isci.2026.115050↗
  3. Tumor gene expression is associated with venous thromboembolism in patients with ductal pancreatic adenocarcinoma. First author DOI 10.1016/j.thromres.2024.109240↗
  4. Kinase activities in pancreatic ductal adenocarcinoma with prognostic and therapeutic avenues. Co-author DOI 10.1002/1878-0261.13625↗
  5. Transcriptome-based classification to predict FOLFIRINOX response in a real-world metastatic pancreatic cancer cohort. Co-author DOI 10.1016/j.trsl.2024.08.002↗
  6. Polymorphisms in transcription factor binding sites and enhancer regions and pancreatic ductal adenocarcinoma risk. Co-author DOI 10.1186/s40246-024-00576-x↗
  7. The PANcreatic Disease ReseArch (PANDoRA) consortium: Ten years' experience of association studies to understand the genetic architecture of pancreatic cancer. Co-author DOI 10.1016/j.critrevonc.2023.104020↗
  8. A scan of all coding region variants of the human genome, identifies 13q12.2-rs9579139 and 15q24.1-rs2277598 as novel risk loci for pancreatic ductal adenocarc… Co-author DOI 10.1093/carcin/bgad056↗
  9. Polymorphic variants involved in methylation regulation: a strategy to discover risk loci for pancreatic ductal adenocarcinoma. Co-author DOI 10.1136/jmg-2022-108910↗
  10. C/EBP-Family Redundancy Determines Patient Survival and Lymph Node Involvement in PDAC. Co-author DOI 10.3390/ijms24021537↗
  11. Analysis of the glyco-code in pancreatic ductal adenocarcinoma identifies glycan-mediated immune regulatory circuits. Co-author DOI 10.1038/s42003-021-02934-0↗
  12. Impact of classical and basal-like molecular subtypes on overall survival in resected pancreatic cancer in the SPACIOUS-2 multicentre study. Co-author DOI 10.1093/bjs/znac272↗
  13. A Paradoxical Role for Regulatory T Cells in the Tumor Microenvironment of Pancreatic Cancer. Co-author DOI 10.3390/cancers14163862↗
  14. Minimally invasive versus open distal pancreatectomy for pancreatic ductal adenocarcinoma (DIPLOMA): study protocol for a randomized controlled trial. Co-author DOI 10.1186/s13063-021-05506-z↗
  15. Association of Genetic Variants Affecting microRNAs and Pancreatic Cancer Risk. Co-author DOI 10.3389/fgene.2021.693933↗
  16. Circulating tumor DNA quantity is related to tumor volume and both predict survival in metastatic pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/ijc.32586↗
  17. Genome-wide association study identifies an early onset pancreatic cancer risk locus. Co-author DOI 10.1002/ijc.33004↗
  18. Macrophage-secreted MMP9 induces mesenchymal transition in pancreatic cancer cells via PAR1 activation. Co-author DOI 10.1007/s13402-020-00549-x↗
  19. Unsupervised class discovery in pancreatic ductal adenocarcinoma reveals cell-intrinsic mesenchymal features and high concordance between existing classificati… Co-author DOI 10.1038/s41598-019-56826-9↗
  20. High-grade mesenchymal pancreatic ductal adenocarcinoma drives stromal deactivation through CSF-1. Co-author DOI 10.15252/embr.201948780↗
  21. CCAAT/Enhancer-Binding Protein Delta (C/EBPδ): A Previously Unrecognized Tumor Suppressor that Limits the Oncogenic Potential of Pancreatic Ductal Adenocarcino… Co-author DOI 10.3390/cancers12092546↗
  22. Do pancreatic cancer and chronic pancreatitis share the same genetic risk factors? A PANcreatic Disease ReseArch (PANDoRA) consortium investigation. Co-author DOI 10.1002/ijc.31047↗
  23. Tumor manipulation during pancreatic resection for pancreatic cancer induces dissemination of tumor cells into the peritoneal cavity: a systematic review. Co-author DOI 10.1016/j.hpb.2017.08.018↗
  24. ADAM12 is a circulating marker for stromal activation in pancreatic cancer and predicts response to chemotherapy. Co-author DOI 10.1038/s41389-018-0096-9↗
  25. Genome-wide meta-analysis identifies five new susceptibility loci for pancreatic cancer. Co-author DOI 10.1038/s41467-018-02942-5↗
  26. Prognostic value of occult tumor cells obtained by peritoneal lavage in patients with resectable pancreatic cancer and no ascites: A systematic review. Co-author DOI 10.1002/jso.24402↗
  27. Functional single nucleotide polymorphisms within the cyclin-dependent kinase inhibitor 2A/2B region affect pancreatic cancer risk. Co-author DOI 10.18632/oncotarget.10935↗
  28. Expression of the antiapoptotic protein BAG3 is a feature of pancreatic adenocarcinoma and its overexpression is associated with poorer survival. Co-author DOI 10.1016/j.ajpath.2012.07.016↗

Closest collaborators

The 25 strongest of 89 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Maarten F. Bijlsma · 13 shared papers, 2018–2026 · strength 1.76
  2. Joanne Verheij · 9 shared papers, 2020–2026 · strength 1.27
  3. Marc G. Besselink · 10 shared papers, 2016–2026 · strength 1.09
  4. Hanneke W.M. van Laarhoven · 7 shared papers, 2018–2026 · strength 0.83
  5. Johanna W. Wilmink · 4 shared papers, 2020–2026 · strength 0.58
  6. Lodewijk A.A. Brosens · 3 shared papers, 2022–2026 · strength 0.57
  7. Mark P.G. Dings · 4 shared papers, 2020–2024 · strength 0.47
  8. Bert A. Bonsing · 3 shared papers, 2022–2025 · strength 0.45
  9. C. Arnold Spek · 3 shared papers, 2020–2023 · strength 0.43
  10. Marjolein F. Lansbergen · 2 shared papers, 2024–2026 · strength 0.41
  11. Paul Manoukian · 2 shared papers, 2024–2026 · strength 0.41
  12. Hans C. Clevers · 2 shared papers, 2022–2026 · strength 0.39
  13. Geert Kazemier M · 2 shared papers, 2022–2026 · strength 0.34
  14. Hanneke W. Wilmink · 3 shared papers, 2018–2025 · strength 0.33
  15. Leonie Hartl · 2 shared papers, 2020–2023 · strength 0.31
  16. JanWillem Duitman · 2 shared papers, 2020–2023 · strength 0.31
  17. Elisa Giovannetti · 2 shared papers, 2022–2024 · strength 0.31
  18. Izaak Quintus Molenaar · 2 shared papers, 2022–2025 · strength 0.30
  19. Jesse V. Groen · 2 shared papers, 2022–2025 · strength 0.30
  20. Eline C. Soer · 3 shared papers, 2020–2022 · strength 0.27
  21. Joep Sprangers · 1 shared paper, 2026 · strength 0.27
  22. Madelon M. Maurice · 1 shared paper, 2026 · strength 0.27
  23. Hans Morreau · 2 shared papers, 2022 · strength 0.26
  24. Vincent Erwin de Meijer · 1 shared paper, 2026 · strength 0.23
  25. Ignace H. J. T. de Hingh · 1 shared paper, 2026 · strength 0.23

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.